- Home
- HSBC vs ABBV Comparison
HSBC vs ABBV Comparison
Compare HSBC & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSBC | ABBV |
|---|---|---|
| Founded | 1865 | 2012 |
| Country | United Kingdom | United States |
| Employees | 209000 | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.6B | 358.5B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | HSBC | ABBV |
|---|---|---|
| Price | $93.56 | $212.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 18 |
| Target Price | N/A | ★ $253.71 |
| AVG Volume (30 Days) | 1.5M | ★ 4.6M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.18% | 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $61,160,000,000.00 |
| Revenue This Year | $14.95 | $11.87 |
| Revenue Next Year | $3.66 | $8.12 |
| P/E Ratio | ★ $94.79 | $556.03 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $58.39 | $181.75 |
| 52 Week High | $94.80 | $244.81 |
Technical Indicators
Market Signals| Indicator | HSBC | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 55.01 |
| Support Level | $88.26 | $211.01 |
| Resistance Level | $94.80 | $213.66 |
| Average True Range (ATR) | 1.46 | 4.83 |
| MACD | 0.17 | 1.19 |
| Stochastic Oscillator | 86.20 | 63.98 |
Price Performance
Historical ComparisonAbout HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and over 40 million customers worldwide. It operates in more than 50 countries with over 200,000 full-time staff. Hong Kong and the United Kingdom are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.